Published in PLOS One on 2026-03-27, this study is presented as an attributed evidence briefing. The excerpts below are the original researchers’ words, reproduced under their Creative Commons Attribution licence. HealthSignal has selected the abstract and, where needed, opening background paragraphs; the complete methods, results, limitations and references remain in the linked paper.
Original authors: Ezekiel Musa, Tawanda Chivese, Mahmoud Werfalli, Larske M Soepnel, Veronique Nicolaou, Mushi Matjila, Shane A Norris, Naomi S Levitt, Marly Cardoso
Source: PLOS One • DOI 10.1371/journal.pone.0345743
Read the complete primary study ↗ · Creative Commons Attribution licence
From the researchers
Abstract
The global prevalence of type 2 diabetes mellitus has significantly risen in recent decades, leading to a corresponding increase in the incidence of diabetes-complicated pregnancies. Hyperglycaemia in pregnancy (HIP), the most common metabolic complication encountered during pregnancy, is associated with a range of adverse maternal and foetal outcomes. This systematic review comprehensively examined the maternal, foetal, neonatal, childhood, and long-term maternal outcomes of HIP in Africa.
A systematic review of all studies investigating HIP outcomes in Africa from January 1998 to February 2025 was undertaken. We searched PubMed-MEDLINE, Cochrane Library, Scopus, CINAHL (EBSCOhost), Embase and Web of Science databases for eligible studies. Studies were included if they were observational studies describing outcomes of HIP in Africa. For each outcome, study results were synthesised using an inverse variance heterogeneity meta-analysis with the Freeman-Tukey transformation. Heterogeneity was assessed using the I2 statistic, and publication bias was assessed using Doi plots.
Thirty studies were included in the review, comprising 9742 participants. These studies were conducted across the following African countries: South Africa (n = 11), Ethiopia (n = 4), Nigeria (n = 3), Sudan (n = 3), Uganda (n = 2), and one each from Ghana, Algeria, Morocco, Democratic Republic of Congo, Zimbabwe, Togo, and Egypt. The most common adverse pregnancy outcomes for gestational diabetes mellitus (GDM) were caesarean section (CS) (overall prevalence 46.0%, 95% CI 35.7–56.4, I2 = 95.6%), preterm delivery (overall prevalence 25.2% (95% CI 12.7–40.2, I2 = 96.7%) and neonatal intensive care unit (NICU) admission (overall prevalence 25.9% (95% CI 13.7–40.2, I2 = 85.7%). The most common adverse pregnancy outcomes for women with preexisting type 1 diabetes (T1DM) were CS (overall prevalence 57.5%, 95% CI 44.9–69.7, I2 = 81.2%), preterm delivery (overall prevalence 50.7%, 95% CI 16.3–84.8, I2 = 92.6%), and neonatal hypoglycaemia (overall prevalence 20.2%, 95% CI 0.0–61.4, I2 = 94.6%). CS (overall prevalence 60.6%, 95% CI 45.5–74.8, I2 = 93.6%) and preterm delivery (overall prevalence 35.2%, 95% CI 29.5–41.1, I2 = 49.3%) were the most prevalent adverse pregnancy outcomes for women with preexisting type 2 diabetes (T2DM). Postpartum T2DM was the most common long-term adverse outcome of women who had GDM or hyperglycaemia first detected in pregnancy (HFDP). There was significant heterogeneity across most outcomes.
The prevalence of adverse outcomes of HIP in Africa is high, in particular CS, preterm delivery and neonatal hypoglycaemia, with higher frequencies in pregestational T1DM and T2DM compared to GDM. Additionally, T2DM prevalence in women post-GDM is about 50%. The outcome data predominantly come from a few studies, indicating the necessity for more high-quality research to improve HIP-related maternal and child health in Africa. The high heterogeneity across most outcomes suggests that their prevalence varies across populations and underscores the need for more high-quality data. PROSPERO Registration Number: CRD42020184573.
Reading this evidence
Use the full paper to check the study design, participant selection, comparator and outcome definitions before drawing a practical conclusion. An association does not by itself show cause and effect. A reported performance measure needs its denominator and uncertainty. A finding from a particular facility, sample or time period should retain that scope when it is discussed elsewhere.
This briefing makes the source accessible within the wider research & evidence desk. It does not assess an individual patient or certify a product. When considering relevance to another health system, examine the original authors’ account of context and limitations, then seek local implementation evidence. The related reporting below provides other studies to read alongside this one; it is a topic connection, rather than a claim that their results are directly comparable.
© 2026 Ezekiel Musa, Tawanda Chivese, Mahmoud Werfalli, Larske M Soepnel, Veronique Nicolaou, Mushi Matjila, Shane A Norris, Naomi S Levitt, Marly Cardoso. Excerpts reproduced under CC BY. Selection, formatting and contextual notes by HealthSignal. The researchers are the authors of the source study, not members of HealthSignal’s staff.
Explore connected evidence
- Evidence brief: The burden of Lipoprotein(a) [Lp(a)] in Africa: A systematic review
- Evidence brief: Prevalence and factors associated with microvascular and macrovascular diabetes complications in adult Ugandans: A systematic review and meta-analysis
- Evidence brief: Effective Coverage of Maternal and Newborn Health Services in Sub-Saharan Africa: What distinguishes high from medium and low performers?
